Bivalirudin during percutaneous coronary intervention in acute coronary syndromes

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Anticoagulant therapy is crucial for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).
• Unfractionated heparin (UFH) has limitations including unpredictable efficacy and risk of bleeding.
• Bivalirudin, a direct thrombin inhibitor, was proposed as an alternative with potential for better outcomes.

Purpose of the Study:

• To review randomized clinical trials comparing bivalirudin and UFH in ACS patients undergoing PCI over two decades.
• To evaluate the efficacy and safety of bivalirudin versus UFH in this patient population.

Main Methods:

• Systematic review and meta-analysis of randomized clinical trials.
• Comparison of bleeding events, stent thrombosis, and overall clinical outcomes between bivalirudin and UFH groups.
• Analysis of trial data considering changes in concomitant therapies like glycoprotein inhibitors (GPI).

Main Results:

• Early trials suggested reduced bleeding with bivalirudin, particularly when combined with GPI.
• Recent studies question bleeding reduction as GPI use declined.
• Concerns regarding increased stent thrombosis risk with bivalirudin emerged.
• Bivalirudin's guideline recommendations have been downgraded.

Conclusions:

• The purported bleeding reduction with bivalirudin is questionable.
• The risk of stent thrombosis with bivalirudin is a significant concern.
• Unfractionated heparin (UFH) provides superior and unparalleled anticoagulation for ACS patients undergoing PCI.